Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate

Por um escritor misterioso
Last updated 19 maio 2024
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Tom Kirrane
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Novel strategies for inhibition of the p38 MAPK pathway: Trends in
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Full article: The p38 MAPK inhibitor BIRB796 enhances the
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Structure-based design, synthesis and biological evaluation of N
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Design, Synthesis, and Biological Activity of Urea Derivatives as
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Molecules, Free Full-Text
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
p38 mitogen‐activated protein kinase: Functions and targeted
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
PDF] Structure-based design, synthesis, and biological evaluation
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
PDF) Clinical candidates of small molecule p38 MAPK inhibitors for
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Figure 1 from 'Reverse' alpha-ketoamide-based p38 MAP kinase
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
p38 MAP kinases: key signalling molecules as therapeutic targets

© 2014-2024 judodevecey.fr. All rights reserved.